The discussion regarding dacomitinib and osimertinib, which is in the field of targeted cancer therapys, has attracted considerable attention.Because both medications fall under the EGFR TKI (TKI) class, they Hence, they make them effective therapys for specific types of lung cancer.This article examines the major distinctions between dacomitinib and osimertinib. It examines their modes of action, effectiveness, adverse effects, and patient factors to consider.A second-generation EGFR TKI, dacomitinib, inhibits the EGFR tyrosine kinase domain, which consequently prevents the activation of EGFR signaling pathway.Osimertinib, also also known as Tagrisso, is a…
